Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Charity 'feels the pinch' of higher energy prices - 225 of the world’s best sandwiches
- 3Israel Police arrest twenty-one as anti-war protests grow despite broad support for Iran war
- 4Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
- 5'Every day I planned an escape': Ariel Cunio shares details of Hamas captivity
- The secret appeal of Harlan Coben’s messy, addictive TV thrillers
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
- Israel strikes Beirut amid rocket fire from Hezbollah and Iran
- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- ‘Harry Potter and the Philosopher’s Stone’ trailer is raising eyebrows among Potterheads: ‘Where’s the whimsical color?’
- Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- Woman gives birth on roadside after hospital allegedly sent her home: Family
